Biliary Tract Cancer
Conditions
Brief summary
To evaluate the efficacy and safety TQB2102 for injection in the treatment of patients with Her2-positive biliary tract cancer.
Interventions
TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
Sponsors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 18 years ≤ age ≤75 years; Eastern Cooperative Oncology Group (ECOG) score 0 to 1; * Subjects must provide sufficient tumor tissue sample and confirm HER2 positivity by central laboratory prior to first dose, defined as immunohistochemistry (IHC) 3+ or IHC 2+ with in situ hybridization (ISH) positive; * The main organs function well; * Meet the criteria for advanced biliary tract cancer: 1. Biliary tract carcinoma confirmed by histology or cytology; 2. Non-operable locally advanced, recurrent and/or metastatic disease with at least one measurable lesion according to Evaluation criteria for the efficacy of solid tumors (RECIST) 1.1 criteria; 3. Failure of 1-2 prior lines of systemic therapy * Women of reproductive age should agree that effective contraception must be used during the study period and for 6 months after the end of the study, and that serum or urine pregnancy tests are negative within 7 days prior to study enrollment; Men should agree that effective birth control must be used during the study period and for 6 months after the end of the study period; * The subjects voluntarily joined the study, signed the informed consent, and the compliance was good.
Exclusion criteria
* Complicated diseases and medical history: 1. Have had or are currently suffering from other malignant tumors within 3 years before the first medication; 2. Unmitigated toxic effects higher than grade 1 of Common Terminology Criteria for Adverse Events (CTCAE) due to any previous treatment; 3. Major surgical treatment, significant traumatic injury, or long-term unhealed wounds or fractures have been received within 4 weeks prior to initial medication; 4. Patients with any bleeding or bleeding events ≥CTCAE grade 3 within 4 weeks before the first dose; Aortic/venous thrombosis events, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, and pulmonary embolism, occurred within 6 months prior to initial administration; Treatment with low molecular weight heparin was permitted and antiplatelet drugs were prohibited throughout the study period; 5. Active viral hepatitis with poor control; 6. There is a history of active tuberculosis, idiopathic pulmonary fibrosis, institutional pneumonia, drug-induced pneumonia, radiation pneumonia requiring treatment or active pneumonia with clinical symptoms; 7. Have a history of psychotropic drug abuse and can not quit or have mental disorders; 8. People who are ready to undergo or have previously received allogeneic bone marrow transplantation or solid organ transplantation; 9. Have a history of hepatic encephalopathy; 10. Currently on or recently used (within 7 days before the start of study treatment) aspirin (\>325 mg/ day (maximum antiplatelet dose) or dipyridamole, ticlopidine, clopidogrel, and cilostazol; 11. Subjects with any severe and/or uncontrolled disease. * Tumor related and treatment: 1. For subjects who have received chemotherapy, immunotherapy within 3 weeks before the first dose, radiation therapy or small molecule targeted drugs within 2 weeks, or who are still within the 5 half-lives of the drug (as the shortest time of occurrence), the washout period is calculated from the end time of the last treatment; 2. Within 2 weeks before the first use of the drug, the treatment of Chinese patent drugs with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions; 3. Imaging including computed tomography (CT) or magnetic resonance imaging (MRI) shows that the tumor has invaded important blood vessels, or the investigator determines that the tumor is highly likely to invade important blood vessels during the follow-up study period and cause fatal massive bleeding; 4. Uncontrolled pleural effusion, pericardial effusion or moderate to severe ascites that still require repeated drainage; 5. Obvious biliary obstruction (except for total bilirubin ≤ 2× upper limit of normal (ULN) after endoscopic stent placement and percutaneous transhepatic biliary drainage); 6. Known spinal cord compression, cancerous meningitis, with symptoms of brain metastases, or symptoms controlled for less than 4 weeks. * Research treatment related: 1. Known allergy to study drug excipients; 2. Have previously received anti-HER2 therapy drugs (only for the second stage, the first stage is not limited); 3. Patients who require immunosuppressive, systemic, or absorbable topical hormone therapy for immunosuppressive purposes and who continue to use it for 7 days prior to initial administration (except for corticosteroids \<10 mg per day of prednisone or other therapeutic hormones). 4. Participants who participated in and used other anti-tumor clinical trials within 4 weeks before the first medication. 5. According to the judgment of the researcher, there is a situation that seriously endangers the safety of the subjects or affects the completion of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and severity of adverse events (AE) and serious adverse events (SAE) | From the time the subject signed the informed consent until 28 days after the last dose/start of the new antitumor therapy | Any adverse medical event that occurred from the time the subject signed the informed consent until 28 days after the last dose/start of the new antitumor therapy (whichever came first). |
| Phase II Recommended Dose (RP2D) | Baseline up to 24 weeks | Phase II Recommended Dose (RP2D) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) | Baseline up to 36 weeks | The percentage of subjects achieving complete response (CR) or partial response (PR) as assessed by the investigator based on the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. |
| Progression-free survival (PFS) | Baseline up to 36 weeks | The time between first medication and first disease progression or death from any cause. |
| Disease control rate (DCR) | Baseline up to 36 weeks | The first assessment was complete response, partial response, and time to disease stabilization. |
| Disease response time (DOR) | Baseline up to 36 weeks | First assessed as complete or partial response to first disease progression or time of death from all causes. |
| Overall survival (OS) | Baseline up to 36 weeks | Time from first use to death from any cause |
Countries
China
Contacts
CONTACTFeng Shen, Doctor
CONTACTJun Zhou, Doctor
Outcome results
None listed